Compare RYZ & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | EVO |
|---|---|---|
| Founded | 1842 | 1993 |
| Country | United States | Germany |
| Employees | 4300 | 4553 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | 2014 | N/A |
| Metric | RYZ | EVO |
|---|---|---|
| Price | $26.40 | $3.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 246.3K | 97.7K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $75.79 | $1.37 |
| Revenue Next Year | $2.17 | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.34 | $2.31 |
| 52 Week High | $28.26 | $4.80 |
| Indicator | RYZ | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 56.90 |
| Support Level | $23.68 | $2.87 |
| Resistance Level | N/A | $3.78 |
| Average True Range (ATR) | 1.08 | 0.11 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 59.31 | 45.10 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.